Tocilizumab, a monoclonal antibody targeting the interleukin-6 receptor (IL-6R), demonstrated clinical benefits in some COVID-19 patients by reducing the hyper-inflammatory responses; however, it was also observed that some patients were refractory to tocilizumab treatment (51, 52). Here, IL6R is linked to COVID-19.